Editorially reviewed by Dr Fatimah Khan, registered with the Pakistan Medical and Dental Council (PMDC no. 104595-P). Editorial medical reviewer; does not prescribe or review patient assessments.
Review details
Review recorded:
Review scope: This article edition.
Editorial reviewer for Prescrivia. Editorial review does not establish participation in patient consultations.
Clinical review does not replace individual medical advice. Prescrivia is a technology intermediary; independent doctors make clinical decisions.
Legal review: Qualified review pending.
Language review: Qualified review pending.
Source and review
Source published:
Attributed source update:
Text edited:
Editorial role: Editorial team. This description does not establish an individual credential or clinical review of this edition.
Read our editorial policy and corrections. Edit dates and source descriptions do not establish qualified review.
What is ceftriaxone used for in gonorrhoea care?
Ceftriaxone is an injectable cephalosporin antibiotic used in gonorrhoea treatment. The CDC's 2021 gonorrhoea guidance recommends ceftriaxone-based treatment for many uncomplicated infections, with decisions affected by infection site, body weight and whether chlamydia has been excluded.
Ceftriaxone also has hospital uses for other bacterial infections, but those regimens should not be copied into a patient guide to uncomplicated gonorrhoea. This article explains the care pathway and does not supply an injection dose.
Diagnosis comes before selecting an antibiotic
Gonorrhoea can affect the genitals, rectum, throat or eyes, and it can occur without symptoms. Testing should reflect the sites of possible exposure. Symptoms alone cannot reliably identify the organism.
Tell the clinician about the sites of exposure, previous treatment, allergies, pregnancy and other medicines. They may arrange testing for other STIs as well.
Resistance changes treatment decisions. Use current local guidance rather than assuming that a recommendation from another country applies unchanged. A phrase such as “current trend toward 1–2 g” cannot replace a specific guideline and indication.
Injection and allergy assessment
An injection requires an appropriate clinical setting and trained staff. An online assessment alone does not administer treatment.
A reported penicillin allergy needs a careful history, including the nature and timing of the reaction. A mild historical rash and a severe immediate reaction are not equivalent. Do not use an unsupported cross-reactivity percentage to decide whether an injection is safe for you.
Partners and follow-up
The NHS gonorrhoea guide explains partner testing and follow-up. The treating service should give specific instructions about avoiding sex and checking that treatment worked. Requirements can differ by infection site and local guidance.
Ask:
- Where will treatment be administered?
- How and when will results be communicated?
- Which partners need testing?
- Is a test of cure or later retesting needed?
Fever, joint pain or swelling, a rash, or eye pain/redness with suspected gonorrhoea needs urgent medical assessment. Do not wait for an online reply if symptoms suggest a more serious infection.
What Prescrivia does
Our online-assessment guide explains the intermediary model. Prescrivia does not employ the doctor making your clinical decision or provide injection services. Independent clinicians determine testing, treatment or referral, and licensed pharmacies dispense where applicable. A prescription, clinic appointment, access or outcome is not guaranteed.
General information only, not medical advice. Follow the leaflet for your actual product and discuss decisions with a qualified clinician. See the current clinical, legal and language review statuses for this edition.
Sources
- US 2021 gonorrhoea guidance: ceftriaxone-based treatment, site and weight distinctions, allergy assessment, coinfection and follow-up.
- NHS patient guidance: testing, urgent symptoms, clinical treatment, partner notification and follow-up.
Sources checked online on 6 October 2026. UK and US guidance is identified as such; it does not establish availability or prescribing rules across all European countries.